A a prospective, non-interventional, qualitative study consisting of in-depth, semi-structured telephone interviews with patients with TRD who had responded to treatment and who were participating in SUSTAIN-3 (NCT02782104), an open-label, long-term extension safety study of ESK plus OAD
Latest Information Update: 11 Mar 2021
At a glance
- Drugs Esketamine (Primary) ; Antidepressants
- Indications Major depressive disorder
- Focus Adverse reactions; Therapeutic Use
- Acronyms STRIVE
- 11 Mar 2021 New trial record